Particle Therapy 2017

Rationale: modern perspectives • The « new » era : since the 2000s: – Need to fight back in the raising competition with IMXRT that also allows safe dose-escalation studies – Need to keep-up with modern « environment » of Rtherapy: easiness, reliability (gantries, absence fiducials), safety and reproducibility (QA, IGRT, adaptive, in vivo dosimetry…) – Need to be evaluated in the full context of multimodal armamentarium…